Article thumbnail

Differential usage of transcriptional start sites and polyadenylation sites in FMR1 premutation alleles†

By Flora Tassone, Silvia De Rubeis, Chiara Carosi, Giorgio La Fata, Gisele Serpa, Christopher Raske, Rob Willemsen, Paul J. Hagerman and Claudia Bagni

Abstract

5′- and 3′-untranslated regions (UTRs) are important regulators of gene expression and play key roles in disease progression and susceptibility. The 5′-UTR of the fragile X mental retardation 1 (FMR1) gene contains a CGG repeat element that is expanded (>200 CGG repeats; full mutation) and methylated in fragile X syndrome (FXS), the most common form of inherited intellectual disability (ID) and known cause of autism. Significant phenotypic involvement has also emerged in some individuals with the premutation (55–200 CGG repeats), including fragile X-associated premature ovarian insufficiency (FXPOI) in females, and the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS), in older adult carriers. Here, we show that FMR1 mRNA in human and mouse brain is expressed as a combination of multiple isoforms that use alternative transcriptional start sites and different polyadenylation sites. Furthermore, we have identified a novel human transcription start site used in brain but not in lymphoblastoid cells, and have detected FMR1 isoforms generated through the use of both canonical and non-canonical polyadenylation signals. Importantly, in both human and mouse, a specific regulation of the UTRs is observed in brain of FMR1 premutation alleles, suggesting that the transcript variants may play a role in premutation-related pathologies

Topics: RNA
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:3152321
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2007). A novel method for poly(A) fractionation reveals a large population of mRNAs with a short poly(A) tail in mammalian cells.
  2. (2008). A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations.
  3. (2009). A review of fragile X premutation disorders: expanding the psychiatric perspective.
  4. (2004). A study of the distributional characteristics of FMR1 transcript levels in 238 individuals.
  5. (2007). Aberrant regulation of messenger RNA 30-untranslated region in human cancer.
  6. (1991). Absence of expression of the FMR-1 gene in fragile X syndrome.
  7. (2010). Advances in understanding the molecular basis of FXTAS.
  8. (1996). Alternative splicing of exon 14 determines nuclear or cytoplasmic localisation of fmr1 protein isoforms.
  9. (1996). Alternative splicing of the FMR1 gene in human fetal brain neurons.
  10. (2006). Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.
  11. (2009). Blocking beta-catenin binding to the ZBP1 promoter represses ZBP1 expression, leading to increased proliferation and migration of metastatic breast-cancer cells.
  12. (2008). CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome.
  13. (1993). Characterization and localization of the FMR-1 gene product associated with fragile X syndrome.
  14. (2000). Chemical stimulation of synaptosomes modulates alpha -Ca2+/ calmodulin-dependent protein kinase II mRNA association to polysomes.
  15. (2005). Computational analysis of 30-ends of ESTs shows four classes of alternative polyadenylation in human, mouse, and rat.
  16. (2009). Dendritic LSm1/CBP80-mRNPs mark the early steps of transport commitment and translational control.
  17. (2004). Developmentally-programmed FMRP expression in oligodendrocytes: a potential role of FMRP in regulating translation in oligodendroglia progenitors.
  18. (2008). Distinct role of long 30 UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons.
  19. (1994). DNA sequence requirements for transcriptional initiator activity in mammalian cells.
  20. (2007). Elevated FMR1 mRNA in premutation carriers is due to increased transcription.
  21. (2000). Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.
  22. (2003). Eukaryotic translation initiation factors and regulators.
  23. (1993). Fine structure of the human FMR1 gene.
  24. (2004). FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ ataxia syndrome (FXTAS).
  25. (2010). Fragile X mental retardation protein control of neuronal mRNA metabolism: Insights into mRNA stability.
  26. (1999). Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study–preliminary data.
  27. (2008). Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function.
  28. (2007). Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines.
  29. (2007). Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1.
  30. (2009). Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies.
  31. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.
  32. (2008). Identifying intrinsic and extrinsic determinants that regulate internal initiation of translation mediated by the FMR1 50 leader.
  33. (2001). Instability of a (CGG)98 repeat in the Fmr1 promoter.
  34. (2005). Localization of FMRP-associated mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons.
  35. (2005). Molecular dissection of the events leading to inactivation of the FMR1 gene.
  36. (2002). Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers.
  37. (1990). Point mutations in AAUAAA and the poly (A) addition site: effects on the accuracy and efficiency of cleavage and polyadenylation in vitro.
  38. (2005). Polymorphic CUG repeats in human mRNAs and their effects on gene expression.
  39. (2004). Redistribution of transcription start sites within the FMR1 promoter region with expansion of the downstream CGG-repeat element.
  40. (2002). Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations.
  41. (2001). Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers.
  42. (2007). Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model.
  43. (2009). RNA-mediated pathogenesis in fragile X-associated disorders.
  44. (2009). Role of 50- and 30-untranslated regions of mRNAs in human diseases.
  45. (2009). Signals, synapses, and synthesis: how new proteins control plasticity.
  46. (2001). The 50-untranslated region of the FMR1 message facilitates translation by internal ribosome entry.
  47. (1991). The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency.
  48. (2005). The emerging fragile X premutation phenotype: evidence from the domain of social cognition.
  49. (2009). The FMR1 gene and fragile X-associated tremor/ataxia syndrome.
  50. (2007). The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines.
  51. (2003). The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses.
  52. (2008). The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP.
  53. (2004). The fragile-X premutation: a maturing perspective.
  54. (2005). The implications of structured 50 untranslated regions on translation and disease.
  55. (2009). The state of synapses in fragile X syndrome.
  56. (2005). The transcriptional landscape of the mammalian genome.
  57. (2009). Tissue and developmental regulation of fragile X mental retardation 1 exon 12 and 15 isoforms.
  58. (2003). Translational control by the 30-UTR: the ends specify the means. Trends Biochem.
  59. (1995). Translational suppression by trinucleotide repeat expansion at FMR1.
  60. (2002). Untranslated regions of mRNAs.
  61. (2007). X chromosome and ovarian failure.